Japan becomes first to approve stem cell therapies for Parkinson’s and heart failure
Japan has granted world-first approval for two stem cell–based regenerative therapies, one for Parkinson’s disease and one for severe heart failure. The Parkinson’s treatment uses induced pluripotent stem cells (iPSCs) that are converted into dopamine-producing neurons and transplanted into the brain to replace cells lost during the disease. The heart failure therapy involves placing sheets of stem cell–derived heart muscle cells onto the heart, which may help restore cardiac function by promoting tissue repair and new blood vessel growth. Both therapies received conditional approval, meaning they can be used clinically while researchers continue to collect additional safety and effectiveness data from patients.
